Table 2.
Univariate and multivariate analysis of S100A7 expression
| Clinical parameters | Univariate | Multivariate | ||
|---|---|---|---|---|
| P value | Relative risk (95% CI) | P value | Relative risk (95% CI) | |
| Relapse-free survival | ||||
| Ki-67 LI (≥15%/<15%) | <0.0001 | 7.3 (3.0–21.7) | 0.0004 | 5.7 (2.1–18.1) |
| S100A7 status (+/−) | 0.0005 | 3.8 (1.8–8.4) | 0.0227 | 2.5 (1.1– 5.9) |
| Lymph node metastasis (+/−) | 0.0006 | 3.6 (1.7–8.0) | 0.0150 | 2.8 (1.2–6.6) |
| Histological Grade (3/1, 2) | 0.0357 | 2.3 (1.1–4.8) | ||
| HER2 status (+/−) | 0.0861 | |||
| ER status (−/+) | 0.0998 | |||
| Menopausal Status (pre/post) | 0.4209 | |||
| Breast cancer survival | ||||
| Ki-67 LI (≥15%/<15%) | 0.0009 | 13.0 (2.5–239.2) | 0.0346 | 7.5 (1.1–150.8) |
| Lymph node metastasis (+/−) | 0.0098 | 5.1 (1.5–23.1) | ||
| S100A7 status (+/−) | 0.0124 | 4.7 (1.4–18.1) | ||
| Histological Grade (3/1,2) | 0.0127 | 4.6 (1.4–17.6) | ||
| ER status (+/−) | 0.1371 | |||
| Menopausal Status (pre/post) | 0.3919 | |||
| HER2 status (+/−) | 0.6477 | |||
Data considered significant (P < 0.05) are shown in boldface type. Parameters with significant values were further examined in the multivariate analysis. Relative risks of only significant values are shown
Abbreviations: ER, Estrogen receptor, HER2 Human epidermal growth factor receptor 2, LI Labeling index